Sunbit offers dental consumers the ability to pay for purchases over time, getting the dental work they need when they need it.

Our patient financing approval rates have doubled with Sunbit…the extremely fast approval process…enables us to fulfill more treatment plans and provide a better experience for patients and staff.

NEW YORK (PRWEB)
November 29, 2021

Industry trailblazer Dental Whale®, which continues to successfully steer dentists in private practice toward better and more efficient business solutions, today announced it has selected Sunbit as its preferred Buy Now, Pay Later (BNPL) solution. Dental Whale is the nation’s leading solutions provider for 19,000+ private dentists and dental support organizations (DSO), providing marketing, scheduling, repair, equipment and technology solutions to improve their practices. Effective today, Dental Whale will recommend Sunbit to all of the dental practices across the U.S. that the company supports.

Dental Whale Leader, Joe Cavarett said, “When we experienced how Sunbit generated increased case acceptance and scheduled treatment for our own Practice Group patients, we wanted to share their financing solution with our members and their patients. Every patient deserves to be given a comprehensive treatment plan and financing options. Sunbit helps practices support the oral health of more patients.”

Sunbit has rapidly become the de facto BNPL leader in the dental industry, with a broad spectrum of patients approved with excellent terms and no hidden fees. Moreover, Sunbit powers the application process and manages the collections process. The dental office gets paid immediately, which contributes directly to the cash flow of the business.    

Based on its own Sunbit pilot program at select locations, Dental Whale confirmed that Sunbit offers access to best-in-class approval rates, terms, and support for dental leaders and their patients. Sunbit offers access to financing for dental procedures with 6, 12, 18 and 24 month payment plan options, and 85% of patients who apply using Sunbit technology are approved. All well-qualified patients get access to 0% for 6- or 12-month payment plans.

“We piloted Sunbit at two of the Dental Whale locations, and we were amazed — in the first 90 days, their technology approved 87% of patients, helping us generate $126K in additional production,“ said Dr. Steven Wingfield, DMD & Practice Management Focus Area Leader at Dental Whale. “Our patient financing approval rates have doubled with Sunbit. Not to mention the extremely fast approval process, which enables us to fulfill more treatment plans and provide a better experience for the patients and staff. We are excited to extend the program to all of our locations,” he added.

Sunbit is proving that Buy Now, Pay Later offers dental practices a valuable new option for dental care financing and access. Sunbit removes the friction from the financing process to make it a closing tool instead of a pain point for patients — reducing embarrassing declines, scrambling for financing alternatives, and treatment delays.

“Dental Whale is a market stand out, and we couldn’t be more excited about their decision,” said Paul Monahan, Executive Director of Business Development, Dental at Sunbit. “We feel like there is significant synergy between our organizations, from Dental Whale’s white glove approach to client support, to its proven ability to benefit a practice’s bottom line, to its philosophy and mission. Today is an exciting first step in what we hope is a long-standing relationship,” he added.

About Dental Whale®

Dental Whale® is simplifying the business of dentistry through learning, shop and solutions. With offices in Texas and Florida, Dental Whale has a suite of solutions that support the success of private practices and DSOs. The company’s mission is to empower dentists by giving them the tools they need to start, grow, and manage their business. At the end of 2020, Dental Whale supported more than 19,000 dentists and helped serve more than 4 million patients. For more information on Dental Whale, call 855-339-3740 or visit https://www.dentalwhale.com/.

About Sunbit

Sunbit is the preferred buy now, pay later technology for everyday needs and services. Sunbit eases the stress of buying everyday things by offering access to fast, fair and transparent payment options to people everywhere. Our technology is offered in-store and online at nearly 9,000 locations, including 1 in 4 auto dealership service centers, optical practices, dentist offices, veterinary clinics and specialty healthcare services. All loans are made by Transportation Alliance Bank, Inc., dba TAB Bank, which determines qualifications for and terms of credit.

Follow Sunbit:

Twitter

LinkedIn

Facebook

Instagram

Media Contact:

media@sunbit.com

Share article on social media or email:

The recent introduction of novel medicines — targeted therapies in particular — has led to improvements in patient care and uncovered new research opportunities, creating a competitive research environment.

TORONTO (PRWEB)
November 29, 2021

Despite the impact on women’s health worldwide, significant unmet needs exist in the diagnosis and treatment of gynecologic cancers. Located in the female reproductive system, many have a reputation for being “silent,” as they are often detected in later stages when treatment options are limited.

However, the recent introduction of novel medicines — targeted therapies in particular — has led to improvements in patient care and uncovered new research opportunities, creating a competitive research environment. With investment in research on the rise, investigators face challenges in patient identification, site selection and an ever-changing regulatory landscape.

Join Premier Research experts, (Moderator) Mary Gunn, PhD, COO, Women’s Health and Diagnostics; Rupa Doshi, PhD, Vice President, Program Strategy, Oncology; Andrew Berchuck, MD, Medical Advisor, Gynecologic Oncology; and Irene Figari, Senior Director, Regulatory Affairs, Premier Consulting, for a live webinar on Wednesday, December 15, 2021 at 11am EST (4pm GMT/UK) on the challenges and opportunities within gynecologic cancer research.

For more information, or to register for this event, visit Addressing the Challenges and Opportunities in Gynecologic Cancer Research.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

This is believed to be the first large-scale analysis of gene expression signatures, tumor cell interactions and T- and B-cell interactions by digital pathology in patients treated with targeted therapy.

TORONTO (PRWEB)
November 29, 2021

Biomarkers are needed to identify patients who benefit most from targeted or immune checkpoint inhibitor (ICI) therapy in metastatic melanoma. This webinar will share an analysis of biomarkers using pre-treatment melanoma samples from the dabrafenib plus trametinib arm of the randomized, Phase III COMBI-v trial using the HALO® image analysis platform combined with gene expression analysis using the Nanostring nCounter technology.

This is believed to be the first large-scale analysis of gene expression signatures, tumor cell interactions and T- and B-cell interactions by digital pathology in patients treated with targeted therapy. Distinct T-cell/B-cell signatures at baseline demonstrated prognostic value, as high T-cell/low B-cell signatures were associated with prolonged survival vs. high T-cell/high B-cell signatures. B cells may be potential biomarkers to identify patients who could achieve improved clinical benefit.

Join this webinar to learn:

• 
  How biomarker analysis with digital pathology coupled with gene expression analysis can identify T- and B-cell signatures with prognostic value in melanoma
• How digital image analysis can identify tumor and stroma compartments and perform cell-by-cell analysis of biomarker positivity within the respective compartments to identify and quantify cellular phenotypes
• How spatial analysis can provide insight into interactions between T- and B-cells

Join Ken Schultz, Principal Scientist, Novartis, for the live webinar on Wednesday, December 15, 2021 at 1pm EST.

For more information, or to register for this event, visit Using Digital Pathology to Determine the Role of Tumor-Infiltrating B-Cells in Clinical Outcomes of Patients with Melanoma.

ABOUT INDICA LABS

Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO® and HALO AI™ for image analysis and HALO Link™ and HALO AP® to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, and toxicological pathology.

To learn more about Indica Labs, visit https://indicalab.com/

Contact:

info@indicalab.com

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

“In conducting this study, our goal is to shed light on the microbial exchanges that occur between pets and pet owners and assess whether pets can mitigate disruption of their owner’s gut microbiome following antibiotic therapy.”

WASHINGTON (PRWEB)
November 29, 2021

The Human Animal Bond Research Institute (HABRI) announced today it has awarded a new research grant, titled “Sharing is caring: can pets protect their owners against antibiotic-associated disruption of the gut microbiome?”, to the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet) to investigate whether pets are a source of microbiota that can help restore deficiencies in their owner’s gut microbiome.

“A growing number of studies have documented the ability of animal contact to impact the human microbiome (collection of microbes in the intestines) in ways that may help prevent certain types of disease, such as cardiovascular disease and asthma,” said Dr. Laurel Redding, VMD, PhD, DACVPM, Assistant Professor of Epidemiology at Penn Vet, the project’s Principal Investigator. “In conducting this study, our goal is to shed light on the microbial exchanges that occur between pets and pet owners and assess whether pets can mitigate disruption of their owner’s gut microbiome following antibiotic therapy.”

This groundbreaking project will follow pet owners over 60 years old who are taking antibiotics for dental implant placement. Antibiotics disrupt the native gut microbiome, which can result in a range of outcomes, from mild diarrhea to severe “C. diff” infection (infection with Clostridioides difficile), and the elderly are particularly at risk for some of these adverse outcomes. Recovery from this type of disruption is not well understood, and factors that promote this recovery are only beginning to be explored. Researchers hypothesize that the gut microbiomes of pet owners and their pets will resemble each other prior to the course of antibiotics, diverge during the disruption phase, then steadily converge during the recovery phase. In demonstrating that animal contact can yield beneficial effects on the restoration of the human gut microbiome, results of this study may reduce concerns about and even promote contact with household pets for older adults. Thus, in addition to other documented mental and physical health benefits, pets may also offer “probiotic” effects to their owners.

“HABRI is proud to fund research that will contribute to our understanding of the physiological health benefits of the human-animal bond,” said Steven Feldman, President, HABRI. “We know that pets and people are good for each other, and it’s exciting that we can still discover new evidence underlying this powerful, mutually-beneficial relationship.”

About the University of Pennsylvania School of Veterinary Medicine

Ranked among the top ten veterinary schools worldwide, the University of Pennsylvania School of Veterinary Medicine (Penn Vet) is a global leader in veterinary education, research, and clinical care. Founded in 1884, Penn Vet is the first veterinary school developed in association with a medical school. The school is a proud member of the One Health initiative, linking human, animal, and environmental health.

Penn Vet serves a diverse population of animals at its two campuses, which include extensive diagnostic and research laboratories. Ryan Hospital in Philadelphia provides care for dogs, cats, and other domestic/companion animals, handling nearly 35,300 patient visits a year. New Bolton Center, Penn Vet’s large-animal hospital on nearly 700 acres in rural Kennett Square, PA, cares for horses and livestock/farm animals. The hospital handles nearly 5,300 patient visits a year, while the Field Service treats more than 38,000 patients at local farms. In addition, New Bolton Center’s campus includes a swine center, working dairy, and poultry unit that provide valuable research for the agriculture industry

About HABRI

HABRI is a not-for-profit organization that maintains the world’s largest online library of human-animal bond research and information; funds innovative research projects to scientifically document the health benefits of companion animals; and informs the public about human-animal bond research and the beneficial role of companion animals in society. For more information, please visit ww.habri.org .

Share article on social media or email: